| Nesiritide: review of clinical pharmacology and role in heart failure management. | |
| | |
MedLine Citation:
|
PMID: 12028606 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nesiritide mimics the actions of endogenous B-type natriuretic peptides. Clinical studies on patients who had acute decompensated heart failure demonstrated rapid-onset dose-related vasodilatory effects. Nesiritide reduces pulmonary capillary wedge pressure and improves dypsnea. These effects compared favorably to standard treatments. It decreases preload and afterload and suppresses the renin-angiotensin-aldosterone axis and the release of norepinephrine. Nesiritide also promotes diuresis and has no proarrhythmic effects. Nesiritide is a valuable therapeutic option in the treatment of patients hospitalized for decompensated heart failure. On-going studies target the examination of its long-term effects on mortality and morbidity and its pharmacoeconomic benefits to the healthcare system. |
| | |
Authors:
|
Judy W M Cheng |
Related Documents
:
|
979066 - The effect of saralasin (1sar-8-ala-angiotensin ii) on blood pressure in patients with ... 17659326 - A 'reverse' phylogenetic approach for identification of novel osmoregulatory and cardio... 11089706 - Evolution and pathophysiology of chronic systolic heart failure. 10760066 - 11beta-hydroxysteroid dehydrogenase in human vascular cells. 22337206 - Hypertension prevalence, awareness, treatment, control, and associated factors in adult... 7428406 - Labetalol ('trandate') in hypertension: a multicentre study in general practice. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Heart disease (Hagerstown, Md.) Volume: 4 ISSN: 1521-737X ISO Abbreviation: Heart Dis Publication Date: 2002 May-Jun |
Date Detail:
|
Created Date: 2002-05-24 Completed Date: 2003-09-26 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100887299 Medline TA: Heart Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 199-203 Citation Subset: IM |
Affiliation:
|
Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and Mount Sinai Medical Center, New York, NY 10029, USA. jcheng@liu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Availability Clinical Trials as Topic Dose-Response Relationship, Drug Drug Administration Schedule Female Heart Failure / diagnosis, drug therapy*, mortality Humans Male Natriuretic Agents / pharmacology*, therapeutic use Natriuretic Peptide, Brain Pharmacology, Clinical* Risk Assessment Severity of Illness Index Structure-Activity Relationship Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Natriuretic Agents; 114471-18-0/Natriuretic Peptide, Brain |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anesthetic considerations in the patient with a heart transplant.
Next Document: Contemporary measures of approach and avoidance goal orientations: similarities and differences.